Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CUMBERLAND PHARMACEUTICALS INC
Report date March 17, 2022 · Filed April 29, 2022
Section 16 reporting ended · disclosed 2022-04-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,473 |
Reported balance
After 2022-03-17 transaction · row 1
1 source rowRow 1 · 2022-03-17 · Other · Disposed 15,000 · Balance 163,473 F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death. |
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2031-03-17 | Direct | 0 |
Reported balance
After 2022-03-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-17 · Other · Disposed 5,000 · Balance 0 F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2022 Filed Apr 29, 2022 17:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherOptions (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-22-026154 · doc4.xml · derivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2031-03-17 F1 · kind: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death. Read SEC document |
| March 17, 2022 Filed Apr 29, 2022 17:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 15,000 | $2.74 | $41,100.00 |
DisclosureSEC source: 0001209191-22-026154 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,473 F1 · kind: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death. Read SEC document |
| December 20, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 314 | $4.33 | $1,359.62 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 14 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,473 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 17, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 240 | $4.17 | $1,000.80 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 13 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,159 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 16, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 240 | $4.53 | $1,087.20 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 12 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,919 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 15, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 200 | $4.29 | $858.00 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 11 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,679 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 14, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 200 | $4.28 | $856.00 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 10 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,479 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 13, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 200 | $4.36 | $872.00 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 9 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,279 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 10, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 90 | $4.82 | $433.80 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 8 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,079 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 09, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 90 | $5.81 | $522.90 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 7 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,989 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 08, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 90 | $6.15 | $553.50 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 6 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,899 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 07, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 90 | $5.61 | $504.90 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 5 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,809 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 06, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 90 | $4.46 | $401.40 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 4 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,719 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 03, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 90 | $4.47 | $402.30 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 3 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,629 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 02, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 90 | $3.84 | $345.60 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,539 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| December 01, 2021 Filed Jan 7, 2022 22:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 90 | $4.14 | $372.60 |
DisclosureSEC source: 0001209191-22-002447 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,449 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 30, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 175 | $4.61 | $806.75 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 21 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,359 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 29, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 175 | $2.23 | $390.25 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 20 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,184 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 26, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 175 | $2.26 | $395.50 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 19 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,009 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 24, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 175 | $2.31 | $404.25 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 18 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,834 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 23, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.29 | $240.45 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 17 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,659 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 22, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.35 | $246.75 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 16 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,554 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 19, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.55 | $267.75 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 15 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,449 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 18, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.58 | $270.90 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 14 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,344 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 17, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.58 | $270.90 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 13 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,239 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 16, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.66 | $279.30 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 12 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,134 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 15, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.71 | $284.55 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 11 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,029 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 12, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.67 | $280.35 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 10 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,924 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 11, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.83 | $297.15 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 9 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,819 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 10, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.94 | $308.70 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 8 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,714 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 09, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.21 | $337.05 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 7 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,609 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 08, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.95 | $309.75 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 6 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,504 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 05, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.71 | $284.55 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 5 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,399 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 04, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.73 | $286.65 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 4 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,294 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 03, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.71 | $284.55 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 3 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,189 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 02, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.63 | $276.15 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,084 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| November 01, 2021 Filed Dec 3, 2021 22:05 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.67 | $280.35 |
DisclosureSEC source: 0001209191-21-067878 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,979 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 29, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.72 | $285.60 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 21 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,874 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 28, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.61 | $274.05 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 20 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,769 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 27, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.61 | $274.05 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 19 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,664 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 26, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.64 | $277.20 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 18 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,559 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 25, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.64 | $277.20 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 17 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,454 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 22, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.66 | $279.30 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 16 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,349 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 21, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.65 | $278.25 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 15 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,244 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 20, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.63 | $276.15 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 14 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,139 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 19, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.76 | $289.80 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 13 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,034 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 18, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.75 | $288.75 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 12 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,929 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 15, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.76 | $289.80 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 11 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,824 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 14, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.81 | $295.05 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 10 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,719 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 13, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.71 | $284.55 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 9 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,614 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.